Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS Inc (DE:135A)
NASDAQ:135A
135A Stock Chart & Stats
€0.64
€0.00(0.00%)
At close: 4:00 PM EST
€0.64
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.48 - €0.98
Previous CloseN/A
Volume0.00
Average Volume (3M)300.00
Market Cap
€30.46M
Enterprise Value€14.49M
Total Cash (Recent Filing)€40.11M
Total Debt (Recent Filing)€2.17M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding44,663,834
10 Day Avg. Volume375
30 Day Avg. Volume300
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)€22.14M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMaterial debt reduction and a sizable equity base provide durable financial flexibility to fund clinical programs or commercialization. Low debt-to-equity (~0.04) reduces solvency risk and the need for urgent refinancing, supporting multi-quarter execution of R&D and go-to-market plans.
Commercial Product Revenue StreamHaving an approved, marketed product establishes a recurring revenue foundation and commercial infrastructure. Brexafemme sales create a sustainable cash inflow and real-world market presence, enabling ongoing customer feedback, prescription growth, and a platform for label expansions or partnership monetization.
Advancing Pipeline (SCY-247)Progressing a second-generation candidate into IV Phase 1 expands the company’s addressable market into invasive candidiasis and prophylaxis. Clinical advancement plus prior Fast Track/QIDP designations enhance long-term commercial and exclusivity prospects, diversifying future revenue beyond the current branded oral product.
Bears Say
Revenue VolatilityLarge swings in top line demonstrate unstable demand or one-off contributors and limit predictability of cash flows. Such volatility makes multi-quarter planning, forecasting, and investment decisions harder and raises execution risk for commercialization and R&D funding strategies.
Negative Free Cash FlowPersistently negative operating and free cash flows, despite improvement, signal ongoing reliance on financing or partnerships to fund operations. Without a sustained FCF turnaround, the company may face dilution risk or constrained investment in trials and commercialization over the medium term.
Weak Profitability/MarginsDeep negative margins and negative returns on equity indicate that core operations are not yet self-sustaining. If margins do not stabilize, earnings weakness will erode the equity base and limit reinvestment capacity, forcing dependence on external capital and increasing dilution risk over time.
SCYNEXIS News
135A FAQ
What was SCYNEXIS Inc’s price range in the past 12 months?
SCYNEXIS Inc lowest stock price was €0.48 and its highest was €0.98 in the past 12 months.
What is SCYNEXIS Inc’s market cap?
SCYNEXIS Inc’s market cap is €30.46M.
When is SCYNEXIS Inc’s upcoming earnings report date?
SCYNEXIS Inc’s upcoming earnings report date is May 18, 2026 which is in 72 days.
How were SCYNEXIS Inc’s earnings last quarter?
SCYNEXIS Inc released its earnings results on Mar 04, 2026. The company reported €0.215 earnings per share for the quarter, beating the consensus estimate of €0.109 by €0.106.
Is SCYNEXIS Inc overvalued?
According to Wall Street analysts SCYNEXIS Inc’s price is currently Overvalued.
Does SCYNEXIS Inc pay dividends?
SCYNEXIS Inc does not currently pay dividends.
What is SCYNEXIS Inc’s EPS estimate?
SCYNEXIS Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SCYNEXIS Inc have?
SCYNEXIS Inc has 44,663,834 shares outstanding.
What happened to SCYNEXIS Inc’s price movement after its last earnings report?
SCYNEXIS Inc reported an EPS of €0.215 in its last earnings report, beating expectations of €0.109. Following the earnings report the stock price went up 0.773%.
Which hedge fund is a major shareholder of SCYNEXIS Inc?
Currently, no hedge funds are holding shares in DE:135A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-16.48%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Options Prices
Currently, No data available
---